RecruitingPHASE1, PHASE2NCT03538899
Autologous Gene Therapy for Artemis-Deficient SCID
Studying T-B+ severe combined immunodeficiency due to gamma chain deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Morton Cowan, MDUniversity of California, San Francisco
- Intervention
- AProArt-CD34(drug)
- Enrollment
- 24 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2038
Study locations (1)
- University of California, San Francisco (UCSF) Children's Hospital, San Francisco, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03538899 on ClinicalTrials.govOther trials for T-B+ severe combined immunodeficiency due to gamma chain deficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03597594Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)St. Jude Children's Research Hospital
- RECRUITINGPHASE1NCT03311503Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan ConditioningDavid Williams
- RECRUITINGNCT00055172Genetic Basis of ImmunodeficiencyNational Heart, Lung, and Blood Institute (NHLBI)
See all trials for T-B+ severe combined immunodeficiency due to gamma chain deficiency →